Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

450
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
450
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

295
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
295
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

569
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
569
Actuarial Approach01:20

Actuarial Approach

218
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
218
Censoring Survival Data01:09

Censoring Survival Data

418
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
418
Life Tables01:22

Life Tables

379
A life table is a statistical tool that summarizes the mortality and survival patterns of a population, providing detailed insights into the likelihood of survival or death across different age intervals within a cohort. By organizing data on survival probabilities and mortality rates, life tables offer a clear snapshot of population dynamics over time. They are extensively used in demography, public health, actuarial science, and ecology to analyze life expectancy, design health interventions,...
379

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of a Moisture-Wicking, Silver-Impregnated Textile in Hospitalized Patients With Intertriginous Dermatitis (ITD): A Single-Case Experiment.

Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Corrigendum to "Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials" [Am Heart J 241 (2021) 108-119].

American heart journal·2025
Same author

NLAS-multi: A multilingual corpus of automatically generated Natural Language Argumentation Schemes.

Data in brief·2024
Same author

Implementing the Brøset Violence Checklist in the ED.

The American journal of nursing·2024
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Dec 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.6K

Estimation on conditional restricted mean survival time with counting process.

Junshan Qiu1, Dali Zhou2, H M Jim Hung3

  • 1Division of Pharmacometrics, OCP/OTS/CDER, US FDA.

Journal of Biopharmaceutical Statistics
|September 7, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces a new non-parametric method to analyze multiple clinical events, offering a clinically meaningful way to quantify treatment effects in longitudinal studies. The method improves upon traditional analyses by not relying on restrictive model assumptions.

Keywords:
Clinical trialscomposite endpointmultiple eventsrestricted mean survival time

More Related Videos

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions
05:18

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

8.7K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K

Related Experiment Videos

Last Updated: Dec 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.6K
Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions
05:18

Measurement of Survival Time in Brachionus Rotifers: Synchronization of Maternal Conditions

Published on: July 22, 2016

8.7K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.4K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Longitudinal Data Analysis

Background:

  • Clinical studies often collect data on multiple events over time to assess disease burden and treatment efficacy.
  • Traditional composite endpoint analysis typically focuses only on the first event, potentially overlooking valuable information from subsequent events.
  • Existing methods for multiple event-time data analysis often depend on model assumptions that can impact treatment effect inferences.

Purpose of the Study:

  • To propose a simple, non-parametric estimator for conditional mean survival time with multiple events.
  • To provide a method for quantifying treatment effects that is clinically interpretable.
  • To address limitations of current analyses that focus solely on the first event in composite endpoints.

Main Methods:

  • Development of a novel non-parametric estimator for multiple event-time data.
  • Utilizing simulation studies to rigorously evaluate the performance and robustness of the proposed method.
  • Application of the new method to real-world data from a cardiovascular clinical trial for practical illustration.

Main Results:

  • The proposed non-parametric method provides a clinically meaningful quantification of treatment effects.
  • Simulation studies demonstrate the effectiveness of the new estimator in analyzing multiple events.
  • The method offers a valuable alternative to traditional analyses, especially when model assumptions are questionable.

Conclusions:

  • The developed non-parametric estimator is a valuable tool for analyzing multiple clinical events in longitudinal studies.
  • This approach enhances the interpretation of treatment effects by considering all events.
  • The method has practical implications for clinical trial design and data analysis, particularly in cardiovascular research.